Creo Medical Group (LON:CREO) Releases Quarterly Earnings Results

Creo Medical Group (LON:CREO) posted its quarterly earnings data on Wednesday. The company reported GBX (2) earnings per share for the quarter, Digital Look Earnings reports. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%.

Creo Medical Group Stock Performance

Shares of CREO stock opened at GBX 9.86 on Thursday. The stock’s 50-day moving average price is GBX 12.70 and its 200 day moving average price is GBX 12.85. The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20. The stock has a market capitalization of £47.90 million, a PE ratio of 9.86 and a beta of 1.56. Creo Medical Group has a 52-week low of GBX 9.50 and a 52-week high of GBX 18.50.

Analyst Ratings Changes

Separately, Shore Capital Group reaffirmed a “house stock” rating and issued a GBX 40 target price on shares of Creo Medical Group in a report on Thursday, July 23rd.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.